Subscribe to Journal
Get full journal access for 1 year
only $20.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Centers for Medicare and Medicaid Services. FY 2020 IPPS Final Rule, CMS-1716-F (2019); https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2020-IPPS-Final-Rule-Home-Page-Items/FY2020-IPPS-Final-Rule-Regulations.html?DLPage=1&DLEntries=10&DLSort=0&DLSortDir=ascending
Verma, S. Aligning payment and prevention to drive antibiotic innovation for Medicare beneficiaries. Health Aff. (Millwood) https://www.healthaffairs.org/do/10.1377/hblog20190802.505113/full/ (2019).
Outterson, K. Innovative ways to pay for new antibiotics will help fight superbugs. STAT https://www.statnews.com/2018/04/11/innovation-new-antibiotics-fight-superbugs/ (2018).
Wennberg, J. E., McPherson, K. & Caper, P. N. Engl. J. Med. 311, 295–300 (1984).
Morrisey, M. A., Sloan, F. A. & Valvona, J. Health Aff. (Millwood) 7, 52–64 (1988).
Liu, Z., Dow, W. H. & Norton, E. C. J. Health Econ. 23, 129–155 (2004).
Chhabra, K. R., Ibrahim, A. M., Thumma, J. R., Ryan, A. M. & Dimick, J. B. Health Aff. (Millwood) 38, 1207–1215 (2019).
Clyde, A. T., Bockstedt, L., Farkas, J. A. & Jackson, C. Health Aff. (Millwood) 27, 1632–1641 (2008).
Rex, J. H. et al. Clin. Infect. Dis. 65, 141–146 (2017).
Powers, J. H., Evans, S. R. & Kesselheim, A. S. Br. Med. J. 360, k587 (2018).
Social Security Act §1886(a)(4) (1989).
DISARM Act (2019).
Ardal, C.O. et al. Revitalizing the antibiotic pipeline: stimulating innovation while driving sustainable use and global access. DRIVE-AB Final Report (European Commission, Innovative Medicines Initiative, 2018).
Outterson, K. et al. PLoS Med. 13, e1002043 (2016).
Outterson, K., Powers, J. H., Daniel, G. W. & McClellan, M. B. Health Aff. (Millwood) 34, 277–285 (2015).
Outterson, K. Cardozo Law Rev. 31, 613 (2010).
Kesselheim, A. S. & Outterson, K. Yale J. Health Policy Law Ethics 11, 101–167 (2011).
O’Neill, J. Tackling drug-resistant infections globally: final report and recommendations (Review on Antimicrobial Resistance, London, 2016).
Clift, C. et al. Towards a new global business model for antibiotics: report from the Chatham House Working Group on New Antibiotic Business Models (London, 2015).
K.O. is the executive director of CARB-X, funded by three governments (US, UK and Germany) and two foundations (Wellcome Trust and Gates). CARB-X is a non-profit accelerator of preclinical and phase 1 antibacterial research that awards grants worldwide.
About this article
Cite this article
Outterson, K. A shot in the arm for new antibiotics. Nat Biotechnol 37, 1110–1112 (2019). https://doi.org/10.1038/s41587-019-0279-8
Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization
Translational Research (2020)
ACS Infectious Diseases (2020)
Open Forum Infectious Diseases (2020)